Chelsea Place Johnson is a principal and focuses on new company formation across areas of unmet medical need. Chelsea is a co-founder and board observer at Judo Bio and a board observer for Chroma Medicine, K36 Therapeutics, Lifordi Immunotherapeutics Rectify Pharmaceuticals, Scorpion Therapeutics, and several stealth newcos.

Prior to joining Atlas Venture in 2019, Chelsea was a member of the founding team at Tango Therapeutics, where she worked in business development. Prior to Tango, Chelsea was a senior associate at Third Rock Ventures where she contributed to the formation of multiple new biotech companies.

Chelsea serves as member of the Q-FASTR steering committee at HMS and as project competition faculty and mentor of the Bridging Academia and Industry program at MGH. Chelsea obtained her PhD from the Biological and Biomedical Sciences program at Harvard University where she received the Ruth L. Kirschstein National Research Service Award. Her doctoral work in the lab of Dr. Levi Garraway focused on genomic and functional genomic studies of uveal melanoma. Chelsea received a BA in biology from Dartmouth College and was elected Phi Beta Kappa. Chelsea spends her free time outdoors with her husband and young children, including on the golf course, ski slopes, and playground.